Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145/LN-145-S1 in Multiple Tumor Types
NCT03449108Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2018
- Primary completion
- Apr 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of LN-145 in ovarian cancer, triple-negative breast cancer (TNBC), anaplastic thyroid cancer (ATC), osteosarcoma (OS), soft tissue sarcoma (STS), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2018; status: active, not recruiting.
02
Drugs
LN-145
03
Conditions
ovarian cancertriple-negative breast cancer (TNBC)anaplastic thyroid cancer (ATC)osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03449108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449108.